MERCK's NEW HEAD OF U.S. PHARMACEUTICAL OPERATIONS IS JOHN ZABRISKIE, PhD, former president of Merck Frosst Canada, who assumes the title of Merck Sharp & Dohme president. Zabriskie, 49, succeeds Douglas MacMaster, who moves to the corporate senior exec level, in one of several executive level appointments announced July 27. The changes becomes effective August 1. Zabriskie assumes his new position after five years as president of Merck Frosst Canada. He joined Merck 23 years ago as a senior chemist and has held positions in quality control, manufacturing and marketing, including an assignment as secretary of the company's New Products Committee, Merck said. Zabriskie holds a doctorate in organic chemistry from the University of Rochester and received his undergraduate degree at Dartmouth. After approximately three years as president of Merck's U.S. drug business, MacMaster moves to corporate senior VP, replacing Howard Powers, who is retiring. MacMaster, 57, will be responsible for manufacturing and technology, Merck Sharp & Dohme AGVET, specialty chemicals, and the Merck Chemical Manufacturing Division. He will report to Merck Chairman and CEO Roy Vagelos. Commenting on MacMaster's performance as head of Merck Sharp & Dohme, Vagelos said: "He has successfully led the division through a time of major new product introductions and competitive challenges to older products . . . Since becoming number one, MSD, under Mr. MacMaster's leadership, has increased its market share and widened the gap between MSD and the number two company." During MacMaster's tenure as head of MS&D since 1985, the company has introduced a wave of major new products, including Vasotec, Prinivil, Mevacor, Pepcid, Noroxin, Primaxin, and Recombivax. John Lyons, 62, formerly executive VP, has been elected vice chairman of the board where he will act as Vagelos' "deputy," Merck explained, "sharing in the board-related workload." Continuing to report to Lyons will be Merck's human pharmaceuticals businesses, and the humans resources function. In addition, Lyons "will continue to play a key role in external affairs," Merck said. He is the chairman-elect of the Pharmaceutical Manufacturers Association. Robert Ingram, formerly VP of government relations for the company, will replace Zabriskie as president of Merck Frosst Canada. Ingram has headed Merck's Washington, D.C. office since 1985. He will report to John Lyons. In moves parallel to the domestic management changes, A. E. Cohen, 51, Merck Sharp & Dohme International President, has been named a corporate senior VP, reporting to Vagelos. "In this new role Cohen will carry out projects and assignments of major strategic and tactical impact of Merck," the company said. "The assignments will span the entire scope of Merck -- human and animal health, specialty chemicals, domestic as well as international." Jerry Jackson, previously senior VP of corporate human health marketing, succeeds Cohen as president of Merck Sharp & Dohme International. Louis Privitere, formerly senior VP of Europe and Africa operations, is appointed senior VP of Merck Sharp & Dohme International, reporting to Jackson. The new VP for international health marketing, Merck Sharp & Dohme International, is David Anstice, who had been managing director of Merck Sharp & Dohme Australia. John Walsh, formerly VP of Merck's Latin America operations, is named senior VP of Europe and Africa for Merck Sharp & Dohme International.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The White House requested $6.8bn for the FDA, down 3.9% from the current funding level, but does not propose any legislative changes. In previous years, the agency used the budget process to seek statutory fixes specific to generic drugs and shortages.
The reductions across medical product programs in the agency’s budget request include hundreds of positions funded by user fees, which may foreshadow its upcoming user fee restructuring strategy.
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
